Stanford's BRP Peptide, Monthly GLP-1 Shots, and the Expanding Obesity Pipeline: April 2026 Peptide Update

Stanford's BRP: AI Discovers a 'Natural Ozempic' Without the Side Effects

The biggest peptide discovery of April 2026 comes from Stanford, where researchers used an AI tool called Peptide Predictor to scan 20,000 human protein-coding genes and identify a novel 12-amino-acid appetite-suppressing peptide called BRP (BRINP2-Related Peptide). Published in Nature, the study shows BRP acts specifically on the hypothalamus — the brain's appetite control center — rather than the broad receptor targets hit by GLP-1 drugs like semaglutide. In lean mice and minipigs, a single BRP injection reduced food intake by up to 50% within one hour. In obese mice, two weeks of daily injections produced significant fat loss with improved glucose and insulin tolerance, without affecting activity levels, water intake, anxiety, or digestion. Crucially, no nausea, constipation, or muscle loss was observed. The senior author has co-founded a company to pursue human clinical trials, though BRP remains preclinical. If the hypothalamus-specific mechanism holds up in humans, BRP could represent a fundamentally different approach to appetite regulation — one that avoids the systemic side effects that limit GLP-1 therapy adherence.

Pfizer's Monthly GLP-1 Shot Enters Phase 3 Territory

Pfizer announced positive Phase 2b VESPER-3 results for PF-08653944 (also called MET-097i or PF'3944), an ultra-long-acting injectable GLP-1 receptor agonist acquired through its $10 billion Metsera purchase. The headline: up to 12.3% mean placebo-adjusted weight loss at 28 weeks, with continued weight loss after patients switched from weekly to monthly dosing — and no plateau in sight. What makes PF'3944 significant is the dosing convenience. Current GLP-1 leaders like semaglutide and tirzepatide require weekly injections, while oral options have food/water restrictions (semaglutide) or are non-peptide (orforglipron). A monthly shot fills an important gap for patients who want infrequent dosing without switching to pills. Pfizer plans 10 Phase 3 trials beginning in 2026, with detailed results to be presented at the ADA Scientific Sessions on June 6, 2026.

Oral Wegovy Launches: OASIS 4 Confirms Pill Matches Injection

Oral semaglutide 25 mg (Wegovy tablet) completed its U.S. launch in January 2026, marking the first oral GLP-1 approved specifically for weight management. The OASIS 4 trial provided the data: 16.6% mean weight loss at 64 weeks in adults with obesity without diabetes, with 79.2% achieving at least 5% weight loss. One-third of adherent participants achieved at least 20% weight loss — numbers that approach injectable semaglutide performance. A notable secondary finding: 71.1% of participants with prediabetes at baseline normalized blood glucose, compared to 33.3% with placebo. The oral Wegovy launch at $149/month (with savings offers) significantly expands GLP-1 accessibility for patients who are needle-averse or prefer pill-based therapy.

CagriSema NDA Under FDA Review: Decision Expected October 2026

Novo Nordisk's CagriSema — a once-weekly combination of cagrilintide 2.4 mg (an amylin analog) and semaglutide 2.4 mg — had its NDA submitted on December 18, 2025, making it the first GLP-1/amylin combination to reach this regulatory stage. The REDEFINE-1 Phase 3 trial showed 22.7% mean weight loss, with 91.9% of participants achieving at least 5% body weight reduction. Under standard 10-month FDA review, a decision is expected around October 2026, though priority review could accelerate the timeline. CagriSema's dual mechanism — combining GLP-1 appetite suppression with amylin's satiety and gastric emptying effects — produced meaningfully more weight loss than semaglutide alone, suggesting the combination approach is more than the sum of its parts.

Pemvidutide: Breakthrough Therapy for MASH and a New Dual Agonist Contender

Altimmune's pemvidutide earned FDA Breakthrough Therapy Designation for MASH (metabolic dysfunction-associated steatohepatitis) in January 2026 — a significant regulatory milestone for a GLP-1/glucagon dual receptor agonist. The compound addresses two major conditions simultaneously: in the Phase 2 MOMENTUM obesity trial (48 weeks), pemvidutide achieved 15.6% weight loss at the highest dose with 78.1% of loss coming from fat; in the Phase 2b IMPACT MASH trial, it significantly improved liver fibrosis markers versus placebo. The fat-to-lean mass loss ratio is particularly notable — pemvidutide's glucagon component appears to boost hepatic fat oxidation while preserving muscle more effectively than pure GLP-1 agonists. Phase 3 trials are planned to begin in 2026.

Myostatin Inhibitors: The Muscle Preservation Play for GLP-1 Weight Loss

One of 2026's most important emerging trends is the pairing of myostatin inhibitors with GLP-1 agonists to address the muscle loss problem. All GLP-1 weight loss drugs cause some lean mass loss alongside fat loss, and the clinical pipeline is responding. Lilly's bimagrumab, a monoclonal antibody targeting both myostatin and activin A, showed superior body composition results in the BELIEVE Phase 2b trial when combined with semaglutide compared to monotherapy. Meanwhile, Scholar Rock's apitegromab — a selective latent myostatin inhibitor approaching a September 2026 PDUFA date for SMA — attenuated lean tissue loss by approximately 55% in the Phase 2 EMBRAZE trial when combined with tirzepatide. These combination approaches may define the next wave of obesity treatment: maximum fat loss with minimal muscle sacrifice.

FDA July 2026 Advisory Panel: 12 Peptides, Two Sessions, Public Comments Open

The FDA Pharmacy Compounding Advisory Committee will meet July 23-24, 2026 to begin reviewing whether 12 peptides should be added to the 503A Bulks List for compounding eligibility. The July session covers seven peptides including BPC-157, TB-500, KPV, and MOTS-c; a second session (before February 2027) will address five more. This follows the February 2026 reclassification that returned approximately 14 peptides to Category 1 compounding eligibility. The FDA has opened docket FDA-2025-N-6895 for public comments, with a deadline of July 9, 2026 for comments to be presented to the committee. Compounding eligibility means licensed pharmacies can legally prepare these substances under physician prescription — it is not equivalent to FDA drug approval, and compounded drugs carry no manufacturer accountability or validated dosing protocols.

Longevity Peptide Combinations Gain Scientific Momentum

The longevity peptide space is maturing from single-compound studies to combination protocols targeting multiple aging pathways. The emerging 'longevity stack' pairing Epithalon (telomere maintenance via telomerase activation), NAD+ precursors like NR (cellular energy and sirtuin activation), and MOTS-c (metabolic fitness and exercise mimicry) represents a multi-pathway approach gaining traction in research circles. MOTS-c research has yielded particularly interesting data: skeletal muscle levels increase 12-fold during exercise, exogenous administration doubled running capacity in mice, and centenarian populations show elevated MOTS-c levels compared to age-matched controls. FOXO4-DRI, the senolytic peptide that selectively clears damaged cells, entered the top 10 evidence-based anti-aging peptides for the first time in 2026. Meanwhile, GHK-Cu's consumer boom continues — a 2024 RCT showed 31% wrinkle reduction and a 2025 meta-analysis of 7 trials (n=456) confirmed the results.

GLP-1 Equity: Drugs Work Across Demographics

A Johns Hopkins Bloomberg School of Public Health study published in 2026 found that GLP-1 receptor agonist drugs are comparably effective across patients of different ages, races, and starting weights, with women experiencing somewhat greater benefit than men. This finding is significant for two reasons: it counters concerns that GLP-1 efficacy might vary meaningfully by demographic, and it supports broader insurance coverage and prescribing across diverse patient populations. Combined with expanding oral options (oral Wegovy, orforglipron) and emerging monthly dosing (PF'3944), the accessibility and equity of GLP-1 therapy is improving on multiple fronts.

AI-Driven Peptide Discovery Is Accelerating

Stanford's BRP discovery underscores a broader trend: artificial intelligence is transforming peptide drug discovery. The Peptide Predictor tool that identified BRP scanned the entire human protein-coding genome (20,000 genes) and predicted 2,683 potential bioactive peptides — any of which could be the next therapeutic candidate. This computational approach compresses years of traditional drug discovery into months. Combined with advances in automated synthesis, high-throughput screening, and AI-enabled structure prediction, the timeline from lead identification to clinical validation is shrinking dramatically. The 2026 Peptide Drug Summit highlighted these emerging solutions as the single biggest shift in the field's trajectory.

What to Watch: Key Dates and Milestones Ahead

The second half of 2026 is packed with peptide milestones. June 6: Pfizer presents detailed VESPER-3 data at ADA Scientific Sessions. July 9: Deadline for public comments on FDA peptide compounding docket (FDA-2025-N-6895). July 23-24: FDA Pharmacy Compounding Advisory Committee meets on BPC-157, TB-500, KPV, MOTS-c, and three other peptides. September 22: PDUFA date for Scholar Rock's apitegromab (myostatin inhibitor) in SMA. October 2026 (estimated): FDA decision on CagriSema NDA. Late 2026: Altimmune expected to initiate pemvidutide Phase 3 program. These events will shape the peptide landscape heading into 2027, with compounding access, combination therapies, and novel mechanisms all in play.

Citations

1. [1] Stanford scientists discover 'natural Ozempic' without side effects. ScienceDaily, April 2026 Source
2. [2] Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust Weight Loss with Monthly Dosing. Pfizer Press Release, February 2026 Source
3. [3] FDA Approves Oral Wegovy — First Oral GLP-1 for Weight Loss. Novo Nordisk, 2025/2026 Source
4. [4] Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH. January 2026 Source
5. [5] Novo Nordisk Files NDA for CagriSema. December 2025 Source
6. [6] OASIS 4: Oral Semaglutide 25 mg in Adults with Overweight or Obesity. PubMed 2026 Source
7. [7] Apitegromab attenuated lean soft tissue loss by ~55% in EMBRAZE Phase 2 trial. Pharmaceutical Technology 2026 Source
8. [8] FDA panel will meet to discuss allowing broader access to certain peptides. STAT News, April 2026 Source
9. [9] GLP-1 Weight-Loss Drugs Comparably Effective Across Age, Race, Starting Weight. Johns Hopkins, 2026 Source

Related Articles

Peptide Guides

GLP-1 Peptides Explained: Semaglutide, Tirzepatide, and Beyond

A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.

PepTracker Pro Team

January 15, 2026 16 min read

glp-1semaglutidetirzepatide

Read

Research Summaries

FDA Peptide Reclassification 2026: What Changed and What It Means

In February 2026, the FDA reclassified 14 peptides back to Category 1 compounding status. Here's what this means for researchers, clinicians, and patients.

PepTracker Pro Team

March 1, 2026 12 min read

fdaregulationcompounding

Read

Research Summaries

Peptide Research in 2026: Key Developments, FDA Changes, and Emerging Compounds

A comprehensive look at the biggest peptide developments of 2026 so far — from FDA approvals and reclassifications to breakthrough clinical trial results and the rise of longevity peptides.

PepTracker Pro Team

April 18, 2026 14 min read

2026FDAGLP-1

Read